Repeat confirmatory testing practices after a reactive rapid HIV test and negative or indeterminate WB/IFA.

<p>WB = Western blot, IFA = Immunofluorescent assay, OF = oral fluid, IND = indeterminate, NEG = negative.</p

Test results for 17 HIV-infected persons with reactive rapid test results initially confirmed as either negative or indeterminate on Western blot or by indirect immunofluorescence, 17 health departments, 11 August 2004 to 31 December 2005.

<p>EIA = enzyme immunoassay, IFA = immunofluorescent assay, WB = Western blot, Neg = Negative, Pos = Positive, Indet = Indeterminate, ND = Not done</p><p>If test result not bracketed, it was conducted by local laboratory.</p>*<p>Bands interpreted as equivocal</p><p>[ ] results reported by CDC lab where Genetic Systems HIV1/HIV2 Plus O and Genetic Systems HIV-1 Westen blot were used unless other test indicated</p>a<p>Vironostika HIV-1 Microelisa System, bioMerieux</p>b<p>Orasure HIV-1 Western blot</p>c<p>Bio-Rad HIV-1/HIV-2 plus O</p>d<p>Genetic Systems HIV-1 Western blot</p>e<p>Fluorognost HIV-1 IFA</p>f<p>Cambridge Biotech HIV-1 Western blot</p>g<p>bDNA Versant HIV RNA Assay (conducted 52 days after initial discordant result-viral load not reported)</p>h<p>Amplicor HIV-1 Monitor v1.5</p>i<p>Genetic Systems rLAV EIA</p>j<p>Multispot HIV-1/HIV-2 rapid test</p>k<p>Unknown</p>l<p>Repeat confirmatory test not done at CDC because initial Western blot found to be positive</p

Demographic, risk, and initial test characteristics of 172 persons with reactive rapid HIV test result and negative or indeterminate confirmatory test and proportion without a repeat confirmatory test; 17 health departments, 11 August 2004 to 31 December 2005.^a

<p>aOR, adjusted odds ratio; CI, confidence interval.</p>*<p>Statistically significant</p>a<p>adjusted for initial confirmatory test result</p>b<p>adjusted for sexual behavior</p

Test results for 12 persons with reactive rapid test results classified as HIV-uninfected but who had an indeterminate WB at the last repeat confirmatory test, 17 health departments, 11 August 2004 to 31 December 2005.

<p>EIA = enzyme immunoassay, WB = Western blot, Neg = Negative, ND = Not done *Bands interpreted as equivocal</p><p>[ ] results reported by CDC lab where Genetic Systems HIV1/HIV2 Plus O and Genetic Systems HIV-1 Western blot were used unless otherwise noted</p>a<p>Vironostika HIV-1 Microelisa System, bioMerieux</p>b<p>Fluorognost Sanochemia IFA</p>c<p>Roche Cobas Amplicor HIV-1 Monitor Assay (ultra-sensitive to 50 copies/ml)</p>d<p>Gen-Probe Procleix HIV-1 RNA Assay</p>e<p>Bio-Rad HIV-1/HIV-2 plus O</p>f<p>Genetic Systems HIV-1 Western blot</p>g<p>Abbott HIVAB HIV-1/HIV-2 (rDNA) EIA</p>h<p>Cambridge Biotech HIV-1 Western blot</p>i<p>OraSure HIV-1 Western blot</p

Demographic characteristics and HIV risk behaviors of 2268 clients whose finger-stick whole blood and oral fluid specimens were tested with the OraQuick Advance rapid HIV test, by state—incidence study, February 2005 through May 2005.

<p>A/PI/AI/AN/Other, Asian/Pacific Islander/American Indian/Alaska Native/Other; IDU, injection drug user; MSM, men who have sex with men; STD, sexually transmitted diseases.</p>a<p>Risk behaviors are not mutually exclusive.</p

Figure 1

<p>Epidemic curve of false-positive OraQuick rapid HIV antibody test results, oral fluid, by Month and Lot, University of Minnesota study, July 2002 through August 2004.</p

Demographic and risk characteristics of 382 clients who had a true-negative or false-positive oral fluid OraQuick Rapid HIV-1 Antibody Test result—University of Minnesota performance study, April 15, 2004 through August 31, 2004.

<p>OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval; A/PI/AI/AN/Other, Asian/Pacific Islander/American Indian/Alaska Native/Other; IDU, injection drug users; MSM, men who have sex with men; STD, sexually transmitted diseases.</p>a<p>Values in bold font represent P≤0.25; variables included in the logistic regression model (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0000185#s2" target="_blank">methods</a>).</p>b<p>Age was categorized into a dichotomous variable with 37 years as the cutoff as this was the median age of performance study clients during both July 1, 2002–April 14, 2004 and April 15, 2004–August 31, 2004.</p>c<p>Risk behaviors are not mutually exclusive.</p>*<p> <i>P</i><0.05</p

OraQuick Advance rapid HIV antibody test results for 2268 clients tested with oral fluid, Incidence Study, February 2005 to June 2005.

a<p>Test line intensity of test device compared to test line intensity of low-positive external control.</p

Eligible newly HIV diagnosed clients verified to have enrolled in HIV care.

<p>Eligible newly HIV diagnosed clients verified to have enrolled in HIV care.</p

Cumulative verified enrollment in HIV care, by study-gender group.

<p>See text for evaluation of differences in functions.</p